Latest News
FDA Approves Keytruda plus Lenvima Combination Treatment for Patients with Certain Types of Endometrial Carcinoma
20 September 2019 - - The US Food and Drug Administration approved the combination of Keytruda, US-based pharmaceutical company Merck's (NYSE: MRK) anti-PD-1 therapy, plus Lenvima, the orally available kinase inhibitor discovered by Eisai, for t...
Case Study of TK216 in Ewing Sarcoma Given at the Children's Oncology Group Meeting
20 September 2019 - - Paul A. Meyers, M.D., chief, Pediatric Sarcoma Service and vice chair for Clinical Affairs of Memorial Sloan Kettering Cancer Center, presented a case study of a patient with Ewing sarcoma who achieved a sustained response follo...
Elysium Health submits BASIS IND to FDA for prevention of AKI in surgical cardiac patients
20 September 2019 - Life sciences company Elysium Health Inc revealed on Thursday that its New Drug (IND) application has been accepted by the US Food and Drug Administration (FDA) to evaluate the efficacy of BASIS for the prevention of acute kidney ...
Portola Pharmaceuticals names new director
20 September 2019 - Portola Pharmaceuticals Inc (Nasdaq: PTLA), a global, commercial-stage biopharmaceutical company, announced yesterday that it has named Ted W Love, MD as a new director.Dr Love has more than 25 years of experience in the discovery...
Graybug Vision starts phase 2a study with GB-102
20 September 2019 - Graybug Vision, a clinical stage pharmaceutical company, has started its phase 2a study with GB-102 in patients with macular oedema derived from diabetic macular oedema or retinal vein occlusion, it was reported yesterday.The prod...